What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of human gastric juice protein. It was first isolated and characterized by Croatian researcher Predrag Sikiric and colleagues in the 1990s, who identified it as a stable fragment of a naturally occurring gastric protein with remarkable tissue-protective and regenerative properties. The full sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
BPC-157 is classified as a research peptide and is not currently approved by the FDA or other regulatory agencies for human therapeutic use. However, it has been extensively studied in animal models across a wide range of injury and disease models, demonstrating consistent and potent tissue-protective, anti-inflammatory, and regenerative effects. Human clinical data is limited but emerging, and BPC-157 has gained significant attention in integrative medicine, sports medicine, and longevity communities for its potential applications in gut healing, tendon and ligament repair, neuroprotection, and systemic anti-inflammatory support.
Note: BPC-157 is a research compound. This article is for educational purposes only. Consult a qualified healthcare practitioner before considering any peptide therapy.
Root Causes Driving Interest in BPC-157
1. Gut Barrier Dysfunction & Inflammatory Bowel Disease
BPC-157 was originally identified in the context of gastric protection — it is derived from a gastric protein and has demonstrated potent gastroprotective effects in animal models of ulcers, IBD, and intestinal injury. The gut is the primary site of BPC-157’s endogenous activity, and conditions characterized by gut barrier dysfunction — leaky gut, IBD, NSAID-induced gastropathy, and chemotherapy-induced mucositis — represent the strongest evidence base for its therapeutic potential.
2. Musculoskeletal Injury & Impaired Tissue Repair
Tendons, ligaments, and muscles have limited blood supply and slow healing rates. Conventional treatments for tendinopathy, ligament tears, and muscle injuries are often inadequate, and many athletes and individuals with chronic musculoskeletal injuries seek alternatives. BPC-157 has demonstrated accelerated healing of tendons, ligaments, muscles, and bone in multiple animal models, making it one of the most studied peptides for musculoskeletal regeneration.
3. Neurological Injury & Neurodegenerative Conditions
Traumatic brain injury, spinal cord injury, peripheral neuropathy, and neurodegenerative conditions are characterized by impaired neuronal repair and chronic neuroinflammation. BPC-157 has demonstrated neuroprotective and neuroregenerative effects in animal models of these conditions, including promotion of axonal regeneration, reduction of neuroinflammation, and protection against excitotoxic neuronal death.
4. Systemic Inflammation & Autoimmune Dysregulation
Chronic systemic inflammation — driven by gut dysbiosis, metabolic dysfunction, environmental toxins, and chronic stress — impairs tissue repair across all organ systems. BPC-157’s broad anti-inflammatory and cytoprotective effects make it relevant as a systemic anti-inflammatory agent in conditions where conventional anti-inflammatory approaches are inadequate or poorly tolerated.
5. NSAID & Medication-Induced Organ Damage
Long-term NSAID use causes gastric ulcers, intestinal permeability, and renal toxicity. Corticosteroids impair wound healing and collagen synthesis. Chemotherapy causes mucositis, neuropathy, and organ toxicity. BPC-157 has demonstrated protective effects against NSAID-induced gastric damage, corticosteroid-impaired wound healing, and chemotherapy-induced organ toxicity in animal models.
Mechanisms of Action
Angiogenesis & Vascular Repair
One of BPC-157’s most consistently demonstrated mechanisms is the promotion of angiogenesis — the formation of new blood vessels. It upregulates vascular endothelial growth factor (VEGF) and its receptor (VEGFR2), stimulating endothelial cell proliferation and migration. This neovascularization is critical for tissue repair, as adequate blood supply is required to deliver oxygen, nutrients, and growth factors to healing tissue. BPC-157-induced angiogenesis has been demonstrated in tendon, muscle, bone, gut, and neural tissue healing models.
Nitric Oxide System Modulation
BPC-157 modulates the nitric oxide (NO) system through multiple mechanisms: it upregulates endothelial NOS (eNOS) activity, increases NO production in vascular endothelium, and protects against NO system dysregulation. This NO-mediated vasodilation and cytoprotection contributes to BPC-157’s gastroprotective, cardioprotective, and tissue-healing effects. BPC-157 appears to normalize NO system activity rather than simply increasing it — it can counteract both NO deficiency and NO excess states.
Growth Factor Upregulation
BPC-157 upregulates multiple growth factors involved in tissue repair: VEGF (angiogenesis), EGF (gut mucosal repair), FGF (connective tissue repair), and IGF-1 (muscle and bone repair). It also upregulates growth hormone receptor expression, potentially amplifying the tissue-repair effects of endogenous GH. This broad growth factor upregulation underlies BPC-157’s ability to accelerate healing across diverse tissue types.
Gut Mucosal Protection & Repair
BPC-157 has demonstrated potent gastroprotective and intestinal healing effects in animal models of gastric ulcers, NSAID-induced gastropathy, IBD, short bowel syndrome, and intestinal anastomosis healing. Mechanisms include: upregulation of COX-2 and cytoprotective prostaglandins, stimulation of intestinal epithelial cell migration and proliferation, enhancement of tight junction protein expression, reduction of intestinal inflammation via NF-κB inhibition, and promotion of mucosal angiogenesis.
Tendon & Ligament Regeneration
BPC-157 has demonstrated accelerated tendon and ligament healing in multiple animal models, including Achilles tendon transection, rotator cuff injury, and ACL repair. Mechanisms include: upregulation of tendon-specific growth factors (TGF-β, PDGF), stimulation of tenocyte proliferation and collagen synthesis, promotion of angiogenesis in avascular tendon tissue, and reduction of inflammatory mediators that impair healing. BPC-157 has also demonstrated the ability to counteract corticosteroid-impaired tendon healing.
Neuroprotection & Neural Regeneration
BPC-157 has demonstrated neuroprotective effects in animal models of traumatic brain injury, spinal cord injury, peripheral nerve crush injury, and neurotoxin exposure. Mechanisms include: reduction of neuroinflammation, promotion of axonal regeneration and Schwann cell proliferation, protection against glutamate excitotoxicity, and upregulation of BDNF and NGF. BPC-157 has also demonstrated antidepressant and anxiolytic effects in animal models through modulation of dopaminergic and serotonergic systems.
Systemic Anti-Inflammatory Effects
BPC-157 reduces systemic inflammation through multiple pathways: inhibition of NF-κB, reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), attenuation of oxidative stress, and modulation of the HPA axis stress response. These systemic anti-inflammatory effects may explain BPC-157’s broad protective effects across organ systems in animal models of inflammatory disease.
Integrative Protocols
Administration Routes & Dosing
BPC-157 is available in two primary forms for research purposes: injectable (subcutaneous or intramuscular) and oral (capsules or sublingual). The oral route is preferred for gut-related applications. Injectable routes are preferred for systemic, musculoskeletal, and neurological applications.
Important note: BPC-157 is not FDA-approved and is classified as a research compound. The following dosing information is derived from animal studies and anecdotal human reports; no standardized human dosing protocols have been established through clinical trials.
- Oral (gut applications): 250–500mcg/day, taken on an empty stomach
- Injectable subcutaneous (systemic/musculoskeletal): 200–500mcg/day, injected near the site of injury or subcutaneously in the abdomen
- Duration: Typically 4–12 weeks for acute injury; longer for chronic conditions
Cross-Link to Hormonal Health Hub
BPC-157 is also covered in the context of therapeutic peptides in the Hormonal Health Hub. See Introduction to Therapeutic Peptides: BPC-157, TB-500 & Tissue Repair for a comprehensive overview of BPC-157 in the context of peptide therapy, including its relationship to TB-500, growth hormone secretagogues, and hormonal optimization protocols.
Synergistic Combinations
- BPC-157 + TB-500 (Thymosin Beta-4): The most studied peptide combination for tissue repair — complementary mechanisms (BPC-157 promotes angiogenesis and local repair; TB-500 promotes systemic cell migration and actin polymerization)
- BPC-157 + Collagen Peptides + Vitamin C: Comprehensive connective tissue repair stack
- BPC-157 + Glutamine + Zinc + Probiotics: Gut repair protocol for leaky gut and IBD
- BPC-157 + NAD+ / NMN: Mitochondrial and cellular repair synergy
Regulatory Status & Safety Considerations
BPC-157 is not approved by the FDA, EMA, or other major regulatory agencies for human therapeutic use. It is classified as a research compound and is not legally available as a dietary supplement in most jurisdictions. Key considerations:
- Source quality: Peptide purity and sterility are critical for injectable use; only pharmaceutical-grade peptides from reputable compounding pharmacies should be considered
- Medical supervision: Injectable peptide therapy should only be undertaken under the supervision of a qualified healthcare practitioner
- Cancer: BPC-157’s pro-angiogenic effects raise theoretical concerns about promoting tumor vascularization; individuals with active cancer should avoid BPC-157 without oncology consultation
- Pregnancy & lactation: No safety data; avoid
- Drug interactions: Limited data; use caution with anticoagulants and immunosuppressants
Key Takeaways
- BPC-157 is a synthetic 15-amino-acid peptide derived from human gastric protein, with potent tissue-protective, anti-inflammatory, and regenerative effects demonstrated in animal models
- Primary mechanisms include angiogenesis promotion via VEGF upregulation, NO system modulation, growth factor upregulation, gut mucosal protection, and systemic anti-inflammatory effects
- Strongest evidence base is for gut healing (ulcers, IBD, leaky gut) and musculoskeletal repair (tendons, ligaments, muscles); neuroprotective effects are promising but less clinically validated
- BPC-157 is not FDA-approved and is classified as a research compound; human clinical trial data is limited
- Oral administration is preferred for gut applications; injectable routes for systemic and musculoskeletal applications
- The BPC-157 + TB-500 combination is the most studied peptide stack for comprehensive tissue repair
- Medical supervision is essential for injectable use; individuals with active cancer should avoid BPC-157 without oncology consultation
- See the Hormonal Health Hub’s Therapeutic Peptides article for BPC-157 in the context of comprehensive peptide therapy protocols
0 comments